Top-News

Acurx Pharmaceuticals Aktie News

Aktie
WKN:  A41DXH ISIN:  US00510M2035 US-Symbol:  ACXP Branche:  Professionelle Dienstleistungen Land:  USA
3,21 $
-0,27 $
-7,76%
2,7568 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
3,28 Mio. €
Streubesitz
70,54%
KGV
-
Index-Zuordnung
-

Acurx Pharmaceuticals News

03.03.25 - PR Newswire
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics PR Newswire
03.03.25 - PR Newswire
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics PR Newswire
28.02.25 - PR Newswire
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update PR Newswire
24.02.25 - PR Newswire
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-​Restorative Potential of Ibezapolstat in the Treatment of CDI PR Newswire
19.02.25 - PR Newswire
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors PR Newswire
07.01.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
06.01.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
06.01.25 - PR Newswire
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »